Cargando…
Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Genética
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036142/ https://www.ncbi.nlm.nih.gov/pubmed/21637572 http://dx.doi.org/10.1590/S1415-47572010005000095 |
_version_ | 1782197858904047616 |
---|---|
author | Paz-y-Miño, César López-Cortés, Andrés Muñoz, María José Castro, Bernardo Cabrera, Alejandro Sánchez, María Eugenia |
author_facet | Paz-y-Miño, César López-Cortés, Andrés Muñoz, María José Castro, Bernardo Cabrera, Alejandro Sánchez, María Eugenia |
author_sort | Paz-y-Miño, César |
collection | PubMed |
description | The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we analyzed exon 18 of the hRAD54 gene, which has been previously reported by our group to carry a silent polymorphism, 2290 C/T (Ala730Ala), associated to meningiomas. We performed a PCR-SSCP method to detect the polymorphism in 239 samples including leukemia and normal control population. The results revealed that the 2290 C/T polymorphism has frequencies of 0.1 for the leukemia and 0.1 for the control group. These frequencies show no statistical differences. Additionally, we dissected the leukemia group in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) to evaluate the polymorphism. The frequencies found in these subgroups were 0.14 for CML and 0.05 for ALL. We found statistically significant differences between CML patients and the control group (p < 0.05) but we did not find significant differences between ALL and the control group (p > 0.05). These results suggest a possible link between the 2290 C/T polymorphism of the hRAD54 gene and CML. |
format | Text |
id | pubmed-3036142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Sociedade Brasileira de Genética |
record_format | MEDLINE/PubMed |
spelling | pubmed-30361422011-06-02 Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia Paz-y-Miño, César López-Cortés, Andrés Muñoz, María José Castro, Bernardo Cabrera, Alejandro Sánchez, María Eugenia Genet Mol Biol Human and Medical Genetics The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we analyzed exon 18 of the hRAD54 gene, which has been previously reported by our group to carry a silent polymorphism, 2290 C/T (Ala730Ala), associated to meningiomas. We performed a PCR-SSCP method to detect the polymorphism in 239 samples including leukemia and normal control population. The results revealed that the 2290 C/T polymorphism has frequencies of 0.1 for the leukemia and 0.1 for the control group. These frequencies show no statistical differences. Additionally, we dissected the leukemia group in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) to evaluate the polymorphism. The frequencies found in these subgroups were 0.14 for CML and 0.05 for ALL. We found statistically significant differences between CML patients and the control group (p < 0.05) but we did not find significant differences between ALL and the control group (p > 0.05). These results suggest a possible link between the 2290 C/T polymorphism of the hRAD54 gene and CML. Sociedade Brasileira de Genética 2010 2010-12-01 /pmc/articles/PMC3036142/ /pubmed/21637572 http://dx.doi.org/10.1590/S1415-47572010005000095 Text en Copyright © 2010, Sociedade Brasileira de Genética. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Human and Medical Genetics Paz-y-Miño, César López-Cortés, Andrés Muñoz, María José Castro, Bernardo Cabrera, Alejandro Sánchez, María Eugenia Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia |
title | Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia |
title_full | Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia |
title_fullStr | Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia |
title_full_unstemmed | Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia |
title_short | Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia |
title_sort | relationship of an hrad54 gene polymorphism (2290 c/t) in an ecuadorian population with chronic myelogenous leukemia |
topic | Human and Medical Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036142/ https://www.ncbi.nlm.nih.gov/pubmed/21637572 http://dx.doi.org/10.1590/S1415-47572010005000095 |
work_keys_str_mv | AT pazyminocesar relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia AT lopezcortesandres relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia AT munozmariajose relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia AT castrobernardo relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia AT cabreraalejandro relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia AT sanchezmariaeugenia relationshipofanhrad54genepolymorphism2290ctinanecuadorianpopulationwithchronicmyelogenousleukemia |